Long-term efficacy of insulin glargine in adult type 1 diabetic patients not controlled on previous treatment

Diabetologia Doswiadczalna i Kliniczna

Volumn 7, Issue 4, 2007, Pages 178-183

  Da̧browski, Mariusz ^a   Nowakowski, Andrzej ^b  

^a NZOZ Center for Medical Genetics   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Hypoglycemia; Insulin glargine; Metabolic control; Weight gain

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; SIDE EFFECT; WEIGHT GAIN;

EID: 36849025383     PISSN: 16433165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. The Diabetes Control and Complications Trial (DCCT) Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. The Diabetes Control and Complications Trial (DCCT) Research Group Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90: 450-459.
3. The Diabetes Control and Complications Trial (DCCT) Research Group Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 1415-1427.
4. De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA 2003; 289: 2254-2264.
5. Lepore M, Pampanelli S, Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
6. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
7. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA; for the U.S. Study Group of insulin glargine in type 1 diabetes less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-643.
8. Hershon KS, Blevins TC, Mayo CA, Rosskamp R. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract 2004; 10: 10-17.
9. Porcellati F, Rossetti P, Pampanelli S. et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21: 1213-1220.
10. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005; 35: 536-542.
11. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A.; on behalf of the European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005; 21: 545-553.
12. Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther 2004; 6: 589-595.
13. Ashwell SG, Amiel SA, Bilous RW. et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006; 23: 285-292.
14. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - The glargine and aspart study (GLASS). Diab Res Clin Pract 2007; 77: 215-222.
15. Schreiber S, Rumann A. Evaluation of the long-term efficacy of insulin glargine (Lantus®) in patients with type 1 diabetes in clinical practice. Diabetes 2003; suppl 1: A456.
16. Albright ES, Desmond R, Bell DSH. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004; 27: 632-633.
17. Stroup J, Kane MP, Busch RS, Bakst G, Hamilton RA. The utility of insulin glargine in the treatment of diabetes mellitus. Pharmacotherapy 2004; 24: 736-742.
18. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 2004; 20: 1703-1710.
19. Distiller LA, Joffe BI. From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia 2006; 49: 2793-2794.
20. Manini R, Forlani G, Moscatiello S, Zannoni C, Marzocchi R, Marchesini G. Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. Nutr Metab Cardiovasc Dis 2006: doi: 10.1016/j.numecd.2006. 07.001.
21. Gomis R, Storms F, Conget I, Sinnassamy P, Davies M; on behalf of the ATLANTUS Study Group Improving metabolic control in sub-optimally controlled subjects with type 1 diabetes: comparison of two treatment algorithms using insulin glargine. Diab Res Clin Pract 2007; 77: 84-91.
22. Grimaldi A, Vialettes B, Blayo A, Brun JM, Halimi S. Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen. Diabetes Metab. 2007; 33: 121-128.
23. Garg SK, Gottlieb PA, Hisatomi ME. et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diab Res Clin Pract 2004; 66: 49-56.
24. Riddle MC, Rosenstock J, Gerich J; on behalf of the Insulin Glargine 4002 Study Investigators: the treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
25. Hamann A, Matthaei S, Rosak C, Silvestre L; for HOE901//4007 Study Group A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26: 1738-1744.
26. Österbrand M, Fahlén M, Odén A, Eliasson B. A method to predict the metabolic effect of changes in insulin treatment in subgroups of a large population based patient cohort. Eur J Epidemiol 2007; 22: 151-157.
27. 1c. Diabetes Care 2003; 26: 881-885.
28. Polskie Towarzystwo Diabetologiczne Zalecenia kliniczne dotycza̧ce postȩpowania u chorych na cukrzycȩ 2007. Diab Dośw Klin 2007; suppl A: A8-A9.
29. American Diabetes Association Clinical practice recommendations 2007. Diabetes Care 2007; suppl. 1: S4-S41.
30. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912.
31. Kurtzhals P, Schäffer L, Sørensen A. et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.